Option chain shows key data for Amplia Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Amplia Therapeutics.

Amplia Therapeutics (OTC:INNMF) Stock, Option Chain

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

News

Movers & Shakers

Intraday Update

Movers

Trading Ideas

General

ADHC

AEMD

AFMJF

AFTM

AGFAF

AGTK

AITX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AMMJ

APAFF

ARDS

ASPCF

ATIS

BERK

BLOZF

BOSQF

BOXL

BRVVF

BVTK

CADMF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNTMF

CORV

EKSO

ELLXF

FALC

FCHS

FITX

FLES

FRIVF

FVVSF

GDOT

GNPT

GRPN

GRSO

HKTTF

HREEF

HRTG

HRVSF

IFRTF

INNMF

JFIN

KOIOS BEVERAGE CORP by Koios Beverage Corp.

KBEVF

KMPH

LATNF

LTMCF

MACK

MDRR

MGXMF

MRIB

MRMD

NKOSF

NMHLY

NMRD

NOSUF

NUGS

NXTTF

OMAG

OTEL

PLHCF

PUFLF

PVSP

PXPP

QMC QUANTUM MINERALS CORP by QMC Quantum Minerals Corp.

QMCQF

QRTEB

REFG

RVLT

SCVPY

SEED

SIPC

SPPDF

THTX

TLRY

TTTSF

VFRM

VREOF

VVCIF

WCVC

WDDMF

ICC INTL CANNABIS CORP by ICC Intl Cannabis Corp.

WLDCF

WRLD

YGYI

ZSAN

ZZHGF

NSLPQ

OTGLY

LCTX

TRXC

Stocks That Hit 52-Week Lows On Thursday

Markets

ACNNF

AESE

AGHI

AIRG

AKER

AMCX

AMRH

AMRK

ANDR

APAAF

ATADF

BNKPF

BOSC

BRGO

CFWFF

CHKIF

CLXT

CNGGF

CPPMF

CPYT

DELRF

DIALF

DLPN

DLUEY

DTNOF

ECIFY

EGRAF

EVLO

FDMF

GARB

GDRZF

GLOP

GMHLF

GNAL

GOHE

GTBP

HAON

HENC

HGHAF

HHPHF

HVBTF

IDXG

IMBBY

IMTV

INAP

INDXF

INND

IPIX

JBFCF

JBFCY

JWCAF

KBSF

KWBT

LKCO

LTBR

LUCRF

GLOBALIVE TECH INC by Globalive Technology Inc.

LVVEF

MCEP

MDTR

MFST

MREO

MRIN

MTFB

NIMU

NOHO

NRGMF

NWCI

OCGN

PHVAF

PMGYF

PPCLY

PRGX

PRLE

PTNYF

PZRXQ

RCKHF

RLBD

RMHB

RVSDF

SCNNF

SITO

SNDL

SNOA

SPLIF

SQNS

Stocks That Hit 52-Week Lows On Tuesday

AMPLIA THERAPEUTICS LTD by Amplia Therapeutics Ltd.

Amplia Therapeutics Ltd

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) weight loss drug Zepbound for treating sleep apnea
What Happened: The FDA&#8217;s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA.
&#8220;Too often, OSA is brushed off as &#8216;just snoring,'&#8221; said Julie Flygare, CEO of Project Sleep, in Eli Lilly&#8217;s press release. The condition affects an estimated 80 million Americans, with 20 million experiencing moderate-to-severe forms.
See Also: <a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance">Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo&#8217;s Dominance</a>
In a separate release, the FDA underscored that Zepbound should be used in conjunction with a reduced-calorie diet and increased physical activity for optimal results.
The approval could significantly impact insurance coverage for Zepbound, potentially including Medicare, which currently restricts coverage for obesity drugs unless approved for additional health benefits, <a href="https://www.cnbc.com/2024/12/20/fda-approves-eli-lillys-weight-loss-drug-zepbound-for-sleep-apnea.html">noted</a> CNBC.
This development also gives Eli Lilly an edge over competitor Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), whose Wegovy isn&#8217;t approved for sleep apnea treatment.
Why It Matters: Zepbound's effectiveness was demonstrated in clinical trials. Results showed that nearly half of patients treated with the highest dose experienced disease resolution, the report noted.
This was defined by a significant reduction in their apnea-hypopnea index (AHI), a key metric in diagnosing OSA.
The approval also comes as Eli Lilly continues to <a href="https://www.benzinga.com/24/12/42370795/investments-in-eli-lillys-production-capabilities-reaches-23-billion-with-additional-3-billion-expansion-at-us-facility">expand its manufacturing capabilities</a>, including a $3 billion investment in Kenosha County, Wisconsin in December, to meet the growing demand for its diabetes and obesity medicines.
In October, Eli Lilly reported <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">third-quarter revenue</a> of $11.44 billion, a 20% increase year-over-year, but missed expectations of $12.10 billion. Zepbound generated $1.26 billion.
Price Action: As per <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, LLY shares increased by 1.35% to $767.76 on Friday. So far this year, LLY has risen by 29.65%.
The latest ratings from B of A Securities, Wolfe Research, and Deutsche Bank set an average price target of $1,004, indicating a potential upside of 30.77%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/LLY/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/21033911/Screenshot-2024-12-21-at-2.09.01%E2%80%AFPM-1024x374.png" alt="" class="wp-image-702686" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41318886/eli-lillys-alzheimers-drug-raises-hopes-but-faces-regulatory-hurdles-in-europe">Eli Lilly&#8217;s Alzheimer&#8217;s Drug Raises Hopes but Faces Regulatory Hurdles in Europe</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Health Care

Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has been accused by Rosa DeLauro of pressuring Republicans to abandon key U.S.-China investment restrictions to safeguard the EV giant's business interests in China.
What Happened: In a letter on Friday, DeLauro, the top Democrat on the House Appropriations Committee, stated that Musk used his influence to have Republicans scrap provisions aimed at regulating U.S. investments in China, reported Reuters.
She pointed to Musk's "extensive investments in China in key sectors" and alleged ties to Chinese Communist Party or CCP leadership.
The controversy centers on Tesla's Shanghai gigafactory, which produces about 50% of Tesla's global automobile output.
See Also: <a href="https://www.benzinga.com/24/12/42633974/tesla-cybertruck-units-reportedly-found-with-cell-dent-issues-ev-giant-starts-replacing-battery-packs">Tesla Cybertruck Units Reportedly Found With Cell Dent Issues: EV Giant Starts Replacing Battery Packs</a>
DeLauro argued that Musk's actions jeopardized critical legislation to safeguard U.S. supply chains and national security, accusing him of &#8221; bullying Republicans into going back on their words."
Musk, in turn, criticized DeLauro on X, formerly Twitter, calling for her expulsion from Congress.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This awful creature needs to be expelled from Congress! Ugh …
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870233561753633123?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Tesla has seen robust sales in China, bolstered by strong demand for its Model Y and Model 3 vehicles. In November, <a href="https://www.benzinga.com/markets/equities/24/12/42438591/teslas-china-sales-recover-model-y-accounts-for-over-60-of-november-sales">Tesla's retail sales in China</a> reached 73,490 units, showing a significant recovery from earlier challenges in 2024.
The EV giant also faces stiff competition from local players like BYD Co., which leads the market, but Tesla's steady increase in weekly insurance registrations—21,900 units in early December—<a href="https://www.benzinga.com/news/global/24/12/42284511/tesla-china-sees-robust-demand-in-q4-with-registrations-up-14-2-yoy-so-far-expert-says-ev-giant-on-track-for-best-quarter-ever">signals growing momentum</a>.
Tesla reported <a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">third-quarter revenue</a> of $25.18 billion marking an 8% year-over-year growth. While the company missed Wall Street estimates, automotive revenue reached $20 billion, up 2% year-over-year.
DeLauro's accusations highlight broader concerns about the risks of U.S. investments in Chinese technology sectors. October rules finalized by the Treasury Department aim to limit such investments in critical areas like artificial intelligence to protect national security.
However, the removal of provisions for outbound investment screening could leave gaps in safeguarding U.S. interests.
Price Action: Tesla&#8217;s stock declined by 3.46% on Friday, ending the session at $421.06. Despite this drop, the company's shares have surged 69.5% since the start of the year, significantly outpacing the Nasdaq 100 index, which has gained 28.68% over the same period, according to <a href="http://pro.benzinga.com/">data from Benzinga Pro</a>.
The latest ratings from Baird, Mizuho, and Goldman Sachs have established an average price target of $446.67, suggesting an upside potential of 5.53%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/TSLA/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/21024505/Screenshot-2024-12-21-at-1.14.58%E2%80%AFPM-1024x374.png" alt="" class="wp-image-702681" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42627985/which-magnificent-7-stock-will-gain-the-most-in-a-santa-claus-rally-28-select">Which Magnificent 7 Stock Will Do Best In Santa Claus Rally? Tesla Edged Out As 28% Select…</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

Tech

TSLA

Elon Musk Accused Of Bullying Republicans To Scrap US-China Investment Safeguards To Protect Tesla's Interests

Comments

Amplia Therapeutics

Amplia Therapeutics (INNMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga